ATXI: Avenue Therapeutics Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand avenuetx.com (ATXI)

The business undervaluation factor based on PEG demonstrates the growth potential of Avenue Therapeutics (ATXI), where the parameter value equals 0.00. Primary threats relate to strict opioid controls and potential safety claims regarding the drugs. Meanwhile, Avenue Therapeutics (ATXI) is optimizing costs by utilizing external cGMP plants for drug production. The startup is currently focusing on FDA approval for medications targeting pain therapy and CNS pathologies.

ATXI (Avenue Therapeutics, Inc.) Price/Earnings to Growth Multiple history from 07/04/2022 to 03/29/2025

Avenue Therapeutics, Inc. (ATXI) - metric breakdowns and financial figures

Summary company analytics:Avenue Therapeutics, Inc
Mass-produced product of avenuetx.com

For Avenue Therapeutics (ATXI), whose profits are constrained by the costs of late-stage neurological drug trials, this indicator becomes a key tool for assessing future value. It compares the current P/E multiple with expected earnings growth, identifying asset undervaluation when the value falls below one. Analyzing the P/E-to-growth ratio allows investors to determine an entry point before the operational leverage is realized.

Competing companies

Growth-Adjusted Market Cap to Net Income Biogen Idec|Neurocrine Corp - Price/Earnings to Growth Multiple|regencellbioscience.com (RGC) - Price to Earnings Adjusted for Growth Rate|AXSM - Price/Earnings to Growth Ratio|ACAD (ACADIA Pharmaceuticals Inc.) - Growth-Adjusted P/E Ratio|Xenon Pharmaceuticals (XENE) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio VKTX|Price/Earnings to Growth Ratio Supernus|Price to Earnings Adjusted for Growth Rate catalystpharma.com CPRX|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics Inc.)|HRMY - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Biohaven Ltd. BHVN|AMLX (Amylyx) - Market Cap to Earnings and Growth Ratio|Trevi Therapeutics Inc - PEG Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Precision Medicines)|AVXL: PEG Multiple|CBLL - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio prothena.com|Price/Earnings to Growth Multiple Alector (ALEC)|Price/Earnings to Growth Multiple ANNX (annexonbio.com)|OMER - Price to Earnings Adjusted for Growth Rate|PEG Multiple NGNE (Neurogene Inc)|PEG Multiple AC Immune S.A. ACIU|VYGR - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio NMRA|SCLX (Scilex Holding Company) - Price/Earnings to Growth Multiple|TVGN (Tevogen Bio Holdings) - Price/Earnings to Growth Ratio|ACOG (Alpha Cognition Corp) - PEG Multiple|Cognition Therapeutics, Inc. - Market Cap to Earnings and Growth Ratio|PEG Multiple IKT|SAVA (Cassava) - Growth-Adjusted Payback Ratio|Assertio Holdings, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio COYA|VistaGen Therapeutics, Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income Ovid Therapeutics OVID|ABOS: PEG Multiple|CervoMed Corporation (CRVO) - PEG Multiple|Price/Earnings to Growth Ratio Alterity Therapeutics Limited|Price/Earnings to Growth Ratio CLNN|PEG Multiple PEPG|JUNS (Jupiter Neurosciences) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Relmada Corp RLMD|PEG Multiple Annovis Bio Corporation ANVS|gracetx.com - PEG Multiple|Firefly Neuroscience, Inc (AIFF) - Price/Earnings to Growth Multiple|Klotho Neurosciences (KLTO) - Price/Earnings to Growth Ratio|NeuroSense Therapeutics, Ltd. - Growth-Adjusted Payback Ratio|RVPH (Reviva Pharmaceuticals Holdings) - PEG Multiple|MetaVia Inc (MTVA) - Growth-Adjusted Market Cap to Net Income|PEG Multiple NRXS|Growth-Adjusted Market Cap to Net Income Helius Medical Technologies Inc.|Price/Earnings to Growth Ratio passagebio.com PASG|NEUP: Growth-Adjusted P/E Ratio|NERV - Price/Earnings to Growth Ratio|Athira - Company Value to Earnings Growth Ratio|ADXN: PEG Multiple|ALZN (Alzamend Neuro, Inc.) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Ratio Cyclerion Therapeutics Inc.|PTIX: Growth-Adjusted Payback Ratio|PEG Multiple KTTA|Company Value to Earnings Growth Ratio CRGT|Price/Earnings to Growth Ratio Brainstorm Cell BCLI|PEG Multiple caratherapeutics.com CARA|Chromocell Therapeutics Corp. - PEG Multiple|eliemtx.com - Company Value to Earnings Growth Ratio|Intra-Cellular Therapies (ITCI) - Price/Earnings to Growth Ratio|LBPH (Longboard) - Price/Earnings to Growth Ratio|MRNS (marinuspharma.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate NKGen Biotech NKGN|Price/Earnings to Growth Ratio NeuroBo Pharma (NRBO)|Company Value to Earnings Growth Ratio SAGE|Synaptogenix, Inc. - Price/Earnings to Growth Multiple|TRVN: Growth-Adjusted P/E Ratio|VIGL - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio WENA (Anew Medical, Inc.)|CERE: PEG Multiple